Lataa...
p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors
Bruton’s tyrosine kinase (BTK) is a non-receptor intracellular kinase playing a key role in the proliferation and survival of normal and malignant B-lymphocytes. Its targeting by Ibrutinib, the first specific inhibitor, represented a turning point for the therapy of certain types of B-cell leukemias...
Tallennettuna:
| Julkaisussa: | Front Cell Dev Biol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8215537/ https://ncbi.nlm.nih.gov/pubmed/34164404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2021.690365 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|